Advertisement
The Company intends to respond to NASDAQ with information that may enablethe Company to maintain its listing on The NASDAQ Global Market; however, ifthe Company's plan for compliance is not satisfactory, the Company has theoption to transfer its ADR listing to the NASDAQ Capital Market, previouslycalled the NASDAQ SmallCap Market.
Advertisement
The NASDAQ Capital Market is a continuous trading market that operates inthe same manner as The NASDAQ Global Market. The NASDAQ Capital Market is notrelated to, nor does it operate similarly to the over-the-counter marketsincluding the OTCBB and Pink Sheets. Should the Company transfer its ADRlisting to The NASDAQ Capital Market, its trading symbol on NASDAQ wouldremain "XTLB," and the Company does not expect any interruption in thetrading of its ADRs.
The NASDAQ Capital Market includes over 500 issuers of a wide range ofcapitalization sizes. A NASDAQ Capital Market security satisfies allapplicable qualification requirements for NASDAQ securities, and allcompanies listed on The NASDAQ Capital Market must meet certain financialrequirements and adhere to NASDAQ's corporate governance standards.
About XTL Biopharmaceuticals Ltd.
XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the acquisition,development and commercialization of therapeutics for the treatment ofneuropathic pain and hepatitis C. XTL is developing Bicifadine, a serotoninand norepinephrine reuptake inhibitor, for the treatment of neuropathic pain.XTL is also developing several novel pre-clinical hepatitis C small moleculeinhibitors. XTL also has an active in-licensing and acquisition programdesigned to identify and acquire additional drug candidates. XTL is publiclytraded on the NASDAQ, London, and Tel-Aviv Stock Exchanges (NASDAQ: XTLB;LSE: XTL; TASE: XTL).
Cautionary Statement
Some of the statements included in this press release, particularly thoseanticipating continued trading of the Company's ADRs on the NASDAQ GlobalMarket, the potential transfer of trading to the NASDAQ Capital Market, theexpected uninterrupted trading of the ADR, and the Company's ability tocomply with NASDAQ Capital Market listing requirements, may beforward-looking statements that involve a number of risks and uncertainties.For those statements, we claim the protection of the safe harbor forforward-looking statements contained in the Private Securities LitigationReform Act of 1995. Risk factors that could adversely affect our operationsare identified from time to time in our reports filed with the Securities andExchange Commission and the London Stock Exchange, including our annualreport on Form 20-F filed with the Securities and Exchange Commission onMarch 23, 2007. Any forward-looking statements set forth in this pressrelease speak only as of the date of this press release. We do not intend toupdate any of these forward-looking statements to reflect events orcircumstances that occur after the date hereof. This press release and priorreleases are available at http://www.xtlbio.com. The information in ourwebsite is not incorporated by reference into this press release and isincluded as an inactive textual reference only.Contact: Ron Bentsur Chief Executive Officer Tel: +1-(845)267-0707 ext. 225 +972-
